Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
Conditions:   Advanced Gastroesophageal Junction Adenocarcinoma;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage IV Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Gastroesophageal Junction Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage III Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Unresectable Gastroesophageal Junction Adenocarcinoma
Intervention:   Biological: Pembrolizumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 23, 2020 / by / in
Comments